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Background: Diabetes mellitus contributes substantially to the non-communicable disease burden in South Africa.
The proposed National Health Insurance system provides an opportunity to consider the development of a
cost-effective capitation model of care for patients with type 2 diabetes. The objective of the study was to
determine the potential cost-effectiveness of adapting a private sector diabetes management programme
(DMP) to the South African public sector.
Methods: Cost-effectiveness analysis was undertaken with a public sector model of the DMP as the intervention
and a usual practice model as the comparator. Probabilistic modelling was utilized for incremental cost-effectiveness
ratio analysis with life years gained selected as the outcome. Secondary data were used to design the model while
cost information was obtained from various sources, taking into account public sector billing.
Results: Modelling found an incremental cost-effectiveness ratio (ICER) of ZAR 8 356 (USD 1018) per life year gained
(LYG) for the DMP against the usual practice model. This fell substantially below the Willingness-to-Pay threshold with
bootstrapping analysis. Furthermore, a national implementation of the intervention could potentially result in an
estimated cumulative gain of 96 997 years of life (95% CI 71 073 years – 113 994 years).
Conclusions: Probabilistic modelling found the capitation intervention to be cost-effective, with an ICER of ZAR 8
356 (USD 1018) per LYG. Piloting the service within the public sector is recommended as an initial step, as this would
provide data for more accurate economic evaluation, and would also allow for qualitative analysis of the programme.
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South Africa is undergoing an epidemiological transition
characterized by a growing burden of non-communicable
diseases [1]. Diabetes mellitus features prominently within
this group. The prevalence of diabetes (type 1 and type 2)
amongst adults (ages 20 to 79 years) in South Africa was
estimated to be 4.3% in 2010 and is expected to rise to
4.9% by 2030 [2]. The disease has also contributed
considerably to mortality - according to Statistics South
Africa, diabetes caused 3.3% of the deaths recorded in* Correspondence: karen.hofman@wits.ac.za
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unless otherwise stated.2008 [3]. The delivery of appropriate care for patients
living with diabetes is thus a major challenge within
South Africa’s health system.
In 2011, the South African National Department of
Health drafted a National Health Insurance (NHI) Policy
“Green” Paper in an effort to establish a more effective,
and equitable, health system. A risk-adjusted capitation
approach was proposed as a possible method of reimburs-
ing accredited providers within the NHI dispensation [4].
Capitation is a form of funding in which health service
providers are paid an agreed upon fixed premium by a
health fund in advance of services delivered to members of
that fund for a specified period [5]. The use of capitation
is wide-spread; elements of risk-adjusted capitation can,
for example, be found in the United Kingdom’s National
Health Service, France’s Assurance-maladie and Israel’sl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tation has been employed as a payment option in Ghana’s
National Health Insurance Scheme [8].
Although the capitation approach creates an obvious
incentive for service providers to deliver care in a cost
effective manner, practicalities relating to the imple-
mentation of a capitation system need to be carefully
addressed. A study of capitated payments relating to the
management of patients with diabetes under Medicare in
the United States, for example, found a risk of overpayment
for the care of relatively healthy patients and a potential for
under-treatment of those patients who were very ill, as the
latter were more expensive to manage [9].
Against this background, yielding ‘best practice’ lessons
from other sectors, including the private sector, with
regards to implementing capitation systems would be
useful. In the South African context, such lessons could
be drawn from the Diabetes Management Programme
(DMP) of the Centre for Diabetes and Endocrinology
(CDE), a private sector healthcare provider. The DMP
was launched in 1994 and has been described as “… a
novel community-based capitation and risk-sharing model
for diabetes management” [10].
Using a managed care approach, each patient enrolled
in the DMP is offered a service package that adheres to
‘Minimum Care Guidelines.’ Medical aid schemes pay a
monthly premium, in advance, for this care at a rate that
is negotiated on an annual basis. However, the service
providers are liable for any costs associated with diabetes-
related emergencies (such as diabetic ketoacidosis) and
are, thus, further incentivized to deliver a high quality
of care. Whilst the clinical care offered through the
DMP closely adheres to the guidelines of the International
Diabetes Federation, distinctive features include the
bundling of services within a capitation package as well
as the inclusion of a risk-sharing/performance incentive
element in the form of the diabetes emergency admission
penalty [10].
The DMP has demonstrated positive clinical results;
five-year outcome data showed a 40% overall reduction
in the hospital admission rates for diagnoses that could
be related to diabetes. Furthermore, 5-year HbA1c levels
showed a drop from 9.2% to 7.7% for patients with type
1 diabetes and from 8.8% to 7.4% for patients with type
2 diabetes [10].
Cost-effectiveness analysis assumes that decision-makers
are seeking to maximize an effect within constrained
resources and assesses whether alternative programmes
are worth implementing by referring to an external stand-
ard [11]. Analyzing the cost-effectiveness of implementing
an adaptation of this private sector clinical management
programme to the public sector could, therefore, provide
meaningful information, particularly in light of the NHI
plan.Aim
The aim of the study was to assess whether a DMP
capitation model, adapted for the South African public
sector setting, was potentially cost-effective.
Methods
The study was undertaken in the form of an economic
evaluation that utilized probabilistic modelling. The analysis
was undertaken for a government perspective, with particu-
lar relevance to the review of health service delivery and
funding in the public sector. Ethical approval for the study
was obtained from the Human Research Ethics Committee
(Medical) of the University of the Witwatersrand.
A flow diagram summarizing the study methodology is
provided in Figure 1. The following key elements described
in the figure are detailed below: (1) model development;
(2) costing; (3) cost consequences analysis; (4) life table
analysis; (5) incremental cost effectiveness ratios (ICERs)
and Willingness-to-Pay (WTP) analysis.
Model development
Secondary data used in the model design were obtained
from published articles with the main source studies
being Distiller et al. [10] and Klisiewicz and Raal [12]
(the latter study sampled 150 patients attending public
sector hospitals in Johannesburg, South Africa).
The ‘comparator’ was a usual practice clinical model
based on the 2002 Society for Endocrinology, Metabolism
and Diabetes of South Africa (SEMDSA) guidelines [13]
adapted for the tertiary-level of care. The ‘intervention’
was the DMP capitation model adjusted for a primary
health care (PHC) setting within the public service setting.
This level of care was chosen because improving delivery
of PHC services is a key focus of the NHI plan. Both
models assumed that service users would be treated as
outpatients.
Several assumptions were made in constructing the
models. Firstly, the comparator model was set at the
tertiary level of care because the studies referenced were
undertaken in tertiary hospital settings. Furthermore, the
2002 SEMDSA guidelines were applied as written. This
does not necessarily reflect the actual adherence to guide-
lines or the current form of practice (updated SEMDSA
guidelines were, for example, published in 2012) [14].
Furthermore, only the management of type 2 DM was
considered as literature related to type 2 DM in the South
African context was readily available. Additionally, it was
assumed that a substantially larger number of the patients
utilizing PHC services for DM management would have
this type of diabetes [15].
Costing
Costing was calculated by following the convention of
identifying, measuring and valuating relevant components
Figure 1 Flow diagram of study methodology.
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the SEDMSA guidelines for the comparator and DMP
‘Minimum Care Guidelines’ for the capitation interven-
tion. This is summarized in Table 1. The main difference
between the two models of care was the addition of train-
ing (based on the relevant CDE training course) and an
incentive bonus (for every patient managed without a
diabetes-related emergency) to the intervention model.
Costs were measured for two consultations per annum,
with relevant examinations and investigations counted
for each visit. Doctors were understood to be internal
medicine specialists in the comparator model and general
medical practitioners in the capitation intervention model.
Furthermore, it was assumed that for the group of 150
patients at least one medical practitioner and one nurse
practitioner would be trained. An incentive bonus was
also applied at an amount equivalent to the training cost
per patient seen.
Secondary data of monthly medication usage were
obtained from the CDE as well as the grey literature
based on research undertaken at the University of the
Witwatersrand [17]. Costing of medication was undertaken




1. Compensation ZAR 488.00
2. Training ZAR 104.00*
3. Investigations ZAR 850.62
4. Medication & consumables ZAR 3 725.53
Total direct costs ZAR 5 168.15
Indirect costs




*Combined training cost (based on the CDE’s 2013 fee structure) for one doctor and onwith the treatment of co-morbidities were not included.
Reference was also made to the national Essential Drugs
Lists and Standard Treatment Guidelines [18]. Consumable
costs were based on an assumed monthly usage of a
hundred component units (glucose strips and lancets) per
patient for self-administered blood glucose tests as well as
syringes and needles for insulin doses (for insulin users).
Valuations were based on cost information from the
Uniform Patient Fee Schedule (UPFS) [19,20] and the
National Health Laboratory Service (NHLS) [21], as well as
data sources of the CDE and the Priority Cost Effective
Lessons for Systems Strengthening South Africa (PRICELESS
SA) initiative (www.pricelesssa.ac.za). Cost valuations were
mainly for 2012, and discounting was not used because the
intervention and associated costs and health impacts were
modeled for one year only. It was assumed that values
would change minimally within this period so there was
no inflation/deflation to a common year. For reporting
purposes, the South African rand (ZAR) to United States
dollar (USD) average exchange rate for 2012 was used.
Exchange rate and gross domestic product (GDP) per
capita data were obtained from the World Bank database
(http://data.worldbank.org).Cost per capita (N = 150)
Comparator Difference
ZAR 432.00 ZAR 56.00 +13.0%
ZAR 0.00 ZAR 104.00 N/A
ZAR 523.06 ZAR 327.56 +62.6%
ZAR 3 223.41 ZAR 502.12 +15.6%
ZAR 4 178.47 ZAR 989.68 +23.7%
ZAR 768.00 ZAR 14.00 +1.8%
ZAR 4 946.47 ZAR 1 003.68
+20.3%
(USD 602.49) (USD 122.25)
e nurse per patient seen.
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Using the clinical information given for both the com-
parator and capitation intervention group, we estimated
10-year risks of cardiovascular mortality using the United
Kingdom Prospective Diabetes Study (UKPDS) risk engine
[22]. Inputs for the risk engine included mean age, ethni-
city, smoking status, diabetes duration, HbA1c, systolic
blood pressure, total cholesterol and high-density lipopro-
tein blood levels. A description, and explanatory details, of
the UKPDS prediction equations can be found in an article
written by Stevens et al. [23].
Health outcomes for all of the engine inputs, except
diabetes duration, were obtained from the main source
papers [10,12]. The estimate for diabetes duration was
taken from an alternative study undertaken on a patient
population similar to that of the comparator study [24].
Final CVD risks were weighted for gender, ethnicity
and smoking status. Cost consequences were then cal-
culated from the UKPDS outputs for the intervention
and comparator models, and worked out as a cost per
1% reduction in absolute risk. These were presented as
intermediate results.
Life table analysis
As part of economic evaluation, a multi-state life table is
often employed to describe the differential morbidity and
mortality experiences of a population under alternative
intervention options [25,26]. In this instance, two life
tables were used - one following the mortality experience
in a reference population (who experience the current
mortality of people with diabetes in South Africa) and the
other a population with diabetes who are exposed to the
capitation intervention model.
Increases in cardiovascular disease (CVD) mortality as a
result of having diabetes were modeled. The mortality rates
in the South African population, as well as the mortality
rates due to ischaemic heart disease (IHD) and stroke, were
obtained from the South African National Burden of Dis-
ease study [27]. Within a standard life table, we separated
CVD mortality from mortality due to other causes:
MT¼MCVDþMother
Where MT = total mortality in age/sex group
MCVD =mortality due to CVD
Mother =mortality due to all other causes
The relative risks of IHD and stroke mortality in
people with diabetes from the Asia Pacific Cohort
Studies Collaboration (APCSC) were applied to these
mortality rates to estimate the mortality due to CVD
in people with diabetes in the life table. The APCSC
was used because it involved a meta-analysis of several
longitudinal studies and hence provided a robustevidence base on which to calculate CVD mortality
rates [28]. The number of people with diabetes was
taken from an analysis of the non-fatal burden of dis-
ease attributed to diabetes in South Africa [29].
MCVD;DM¼MCVDxPRMCVD;DM
Where: MCVD,DM = Mortality rate due to CVD in
population with diabetes
MCVD =Mortality rate due to CVD in population
RRMCVD,DM = Relative risk of mortality due to CHD in
population with diabetes
A ratio between the comparator and capitation inter-
vention groups was used to calculate the relative re-
duction in mortality due to CVD expected as a result
of the intervention. These reductions were applied to
the CVD mortality rates in the life table and compari-
sons were made; comparisons included numbers of in-
dividuals surviving, cumulative years lived and life
expectancy. Age categories in the life tables com-
menced from the 25–34 year group because inclusion
of younger age groups resulted in a substantial over-
estimation of years of life gained.
RRm¼MiMc
Where: RRm =mortality risk reduction
Mi =mortality risk in intervention group
Mc =mortality risk in comparator group
Life tables were developed to estimate the impact of the
capitation intervention on life expectancy and number of
life years gained. A life table is generally used to estimate
the mortality experience of a population and to calculate
life expectancy at birth [30]. A life table calculates life
expectancy using the formula [31]:
ex¼Txlx
Where: ex = life expectancy at age x
Tx = cumulative person years lived after age X
lx = individuals alive at beginning of age x
A difference in cumulative person years lived after age
25 between the intervention and comparator populations
were used in the ICER analysis.
ICER and WTP analysis
ICER analysis was undertaken by comparing the costs of
the models to the final effect measure of life years gained
(LYG), with life table outputs being used to derive the
Volmink et al. BMC Health Services Research 2014, 14:444 Page 5 of 9




Where: I cost = cost of the intervention (that is, the
adapted DMP model)
Ccost = cost of the diabetes management (public sector)
comparator
Ieffect = LYG from the comparator
Ceffect = LYG from the comparator
Probabilistic sensitivity analysis was undertaken using
a boot-strapping process. A probabilistic approach was
adopted because of the level of uncertainty in the model-
ling. Indeed, probabilistic sensitivity analysis has been
described as a more robust way of dealing with parameter
uncertainty as compared to standard sensitivity analytical
approaches [11]. Uncertainty values being included for
fatal CHD and strokes parameters, as well as for the per
capita costs of the models (as shown in Table 2).
Modelling also allowed for Willingness-to-Pay (WTP)
analysis. The WHO classifies a ‘highly cost-effective’ inter-
vention as one that costs less than the national GDP per
capita value [33]. Using this as definition, the outputs of
the bootstrapping process were used to determine if the
intervention fell below the WTP threshold.
Software and computing
Microsoft Excel® was the main software application utilized
for data capture and analysis. Ersatz (www.epigear.com), aTable 2 Uncertainty parameters used in sensitivity analysis
Data source Parameter
APCSC study [28] Hazard ratio of fatal CHD
Hazard ratio of fatal CHD
Hazard ratio of fatal stro
Hazard ratio of fatal stro
Intervention model (UKPDS risk engine output) Absolute risk of fatal CH
Absolute risk of fatal CH
Absolute risk of fatal stro
Absolute risk of fatal stro
Comparator model (UKPDS risk engine output) Absolute risk of fatal CH
Absolute risk of fatal CH
Absolute risk of fatal stro
Absolute risk of fatal stro
Intervention model (costing) Per capita cost
Comparator model (costing) Per capita costboot-strap software add-in for Excel, was also used for
uncertainty analysis.
Results
The results as described below in terms of: (1) the costs
of the models; (2) the cost consequences related to CVD
risk reduction (intermediate results); (3) the life table
modelling and, finally, (4) the ICER and WTP results.
Costs of models
The annual per capita cost of intervention model was
ZAR 5950 (USD 725) while that of the comparator was
ZAR 4946 (USD 602), representing a cost increase of
20.3%. More detailed costs are displayed in Table 3.
Apart from the obvious discrepancy of training costs,
the greatest differences observed are in the categories of
medication and consumables, and investigations.
Cost consequences results
The 10-year absolute risk reductions of CVDs potentially
offered by the capitation intervention were projected by
using the UKDPS risk engine (Table 4). The specific CVD
outcomes analyzed by the engine are: coronary heart dis-
ease (CHD), fatal CHD, stroke and fatal stroke. The pro-
jected cost consequences per 1% absolute reduction in risk
of the individual outcomes are reported as intermediary re-
sults. Costs associated with reductions in CHD (fatal and
non-fatal) were substantially lower than those associated
with stroke. The cost consequences of a 1% absolute risk
reduction for fatal CHD, for example, was ZAR 374 (USD
46) and ZAR 667 (USD 81) for males and females respect-
ively, compared to ZAR 3346 (USD 408) for males and
ZAR 5018 (USD 611) for females for fatal stroke.Mean value Lower and upper uncertainty
values (Ersatz output)
in males 2.03% −0.11% 4.41%
in females 2.54% −0.85% 6.42%
ke in males 2.00% −1.90% 5.13%
ke in females 2.04% −0.71% 5.04%
D in males 6.06% 3.92% 8.50%
D in females 3.28% 2.21% 4.27%
ke in males 0.83% 0.76% 0.92%
ke in females 0.62% 0.54% 0.71%
D in males 8.74% 5.57% 11.66%
D in females 4.78% 3.02% 6.41%
ke in males 1.13% 0.94% 1.29%
ke in females 0.82% 0.73% 0.94%
ZAR 5950 ZAR 5401 ZAR 6533
ZAR 4946 ZAR 4467 ZAR 5392
Table 3 Cardiovascular disease risk reduction and cost consequences
10- Year risk: Mean % (Standard Error) Absolute risk reduction Cost consequence
Intervention Comparator Percentage Per 1% risk reduction
Coronary Heart Disease (CHD)
Males 9.92 (0.93) 13.05 (1.23) 3.13 ZAR 320.97
Females 5.36 (0.49) 7.11 (0.70) 1.76 ZAR 571.70
Fatal CHD
Males 6.06 (0.60) 8.74 (0.96) 2.68 ZAR 374.01
Females 3.28 (0.32) 4.78 (0.55) 1.50 ZAR 667.19
Stroke
Males 6.40 (0.21) 7.12 (0.26) 0.72 ZAR 1397.88
Females 4.54 (0.13) 5.05 (0.20) 0.51 ZAR 1960.31
Fatal Stroke
Males 0.83 (0.03) 1.13 (0.05) 0.30 ZAR 3345.60
Females 0.62 (0.03) 0.82 (0.03) 0.20 ZAR 5018.40
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Summary results of the life tables for males and females
are displayed in Table 4. As shown in the table, the
intervention yielded a gain of life years and an increase
in life expectancy in all categories (particularly the
45 – 64 year age bands). Furthermore, a greater benefit
was seen in females as compared to males.Table 4 Summary of life table results
Males
Age (X) Reported Population Individuals with d
A – Individuals surviving
A BB – Cumulative years lived
C – Remaining life expectancy at age X
25-34 37654 37 654 15
35-44 116478 36837 11
45-54 176800 34930 78
55-64 170466 31632 45
65-74 115191 23962 17
75+ 57486 7685 15
Females
Age (X) Reported Population Individuals with d
A – Individuals surviving
A BB – Cumulative years lived
C – Remaining life expectancy at age X
25-34 70088 70088 32
35-44 208972 68531 25
45-54 284081 66330 18
55-64 242488 63398 11
65-74 173947 55288 59
75+ 114595 33421 14ICER and WTP results
Probabilistic modelling was used for ICER analysis. This
gave an ICER mean of ZAR 8 356 (USD 1018) per LYG
(95% CI ZAR 2 794 - ZAR 14 811) by the capitation inter-
vention. Furthermore, it was projected that a national
programme based on the intervention would cost ZAR 792
million (USD 97 million) above the estimated baseline/iabetes Individuals on intervention
C A B C
15469 40.2 37654 1541953 41.0
43011 31.0 36846 1169453 31.7
4172 22.4 34986 810293 23.2
1359 14.3 31889 475917 14.9
3390 7.2 24859 192175 7.7
155 2.0 9357 21094 2.3
iabetes Individuals on intervention
C A B C
01030 45.7 70088 3273923 46.7
07937 36.6 68544 2580762 37.7
33631 27.6 66400 1906039 28.7
84986 18.7 63693 1255573 19.7
1552 10.7 56402 655097 11.6
8007 4.4 36533 190422 5.2
Figure 2 Willingness-to-Pay analysis (using WHO standard [33]).
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resulting in a total cost of ZAR 4.7 billion (USD 576
million), and would result in a mean cumulative gain of
96 997 years of life (95% CI 71 073 years – 113 994 years)
in the population of people living with diabetes.
The results of the WTP analysis are shown in Figure 2.
Bootstrapping analysis (using 1000 iterations) showed all it-
erations of the intervention to be below South Africa’s 2012
GDP per capita and, hence, below the WTP threshold (in
terms of the WHO’s “highly-cost effective” definition [33]).
Discussion
The study demonstrates the potential utility of a DMP
model, adapted for the PHC level, within the South African
public sector. As shown in the modelling, all iterations of
the intervention fell below the accepted WTP threshold.
This finding, together with the life table results, indicates
that the intervention could contribute to increasing life
expectancy in South Africa (one of the strategic outputs
of the Negotiated Service Delivery Agreement [34]) in a
manner that is cost-effective.
Capitation models are used in the provision of health
care in many countries [6]. Furthermore, implementing
capitation systems has been employed as a component
of health care reform. In New Zealand, for example, a
strategic shift towards capitation formed an important
part of the country’s Primary Care reforms [35], and in
Thailand the use of a contract capitation model has been
integral to its Social Health Insurance scheme [36].
Although the current NHI policy paper discusses the
use of a risk-adjusted capitation model in the payment
mechanism [4], implementing such a system in South
Africa would present considerable challenges. Indeed,
in reflecting on the first eighteen months of NHI devel-
opment it has been acknowledged that the envisioned
methods of provider payment “introduce considerable
complexity into the negotiation … and it will take time
to implement payment reforms” [37].This will, undoubtedly, be compounded by the concomi-
tant, and urgent, need to reduce the growing non-
communicable disease burden. Against this background,
the pertinence of the 2011 South African Declaration on the
Prevention of Non-Communicable Diseases commitment to
“[r]educing costs and (increasing) the efficiency of health in-
terventions” can be appreciated [38]. The capitation inter-
vention model analyzed in this paper may be of some
assistance in fulfilling this commitment, at least with respect
to the care of patients with diabetes in the public sector.
In addition to its potential cost-effectiveness, the capi-
tation intervention could also contribute to a broader
improvement in the quality of patient care. The DMP has
been described as a managed care model driven, at least
in part, by a desire to produce good outcomes for patients
[10]. This is reflected in a commitment to individual
professional development as well as the fostering of ef-
fective clinical teams. Enhancement of motivation, team
dynamics and staff morale could thus be considered as key
features of the model; it can perhaps be viewed as a holistic
programme with the capitation element representing only
one facet. Whilst these factors may be economically intan-
gible, they are no less important particularly in light of the
proposed performance-based mechanism in the NHI plan
[4] and may, in fact, be essential to the model’s effective
implementation in the public sector.
Challenges around adapting the CDE penalty system
also merit discussion. One of the presumed strengths of
the DMP model, as currently practised, is the inclusion of a
penalty for diabetes emergencies. However, the application
of such a disincentive in the public service setting is likely
to be untenable as services in this sector are, by definition,
not profit driven. For this reason, an incentive bonus per
consultation for every patient successfully managed without
a diabetes-related emergency was used as a proxy in this
study. While the inclusion of such an incentive bonus may
be debatable, and the actual type of incentive could vary,
it is not without precedent [39]. The Practice Incentives
Program of the Department of Human Services of the
Australian Government, for example, appears to be based
on a comparable incentive approach [40].
Limitations
There are several limitations that apply to this study.
Firstly, while it would have been preferable to use a
comparator model that was at the same level of care as
that of the intervention (that is, a primary care comparator)
it was difficult to obtain relevant data to do so because of
the paucity of relevant studies in the South African context.
Furthermore, the intention was to develop the intervention
and comparator as closely as possible to the actual service
models used in the respective studies. Modelling primary
health centre care as a comparator would have introduced
additional uncertainty and required further assumptions.
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lent for all of the cost components of the DMP. The
cost, for example, of a dedicated 24-hour diabetes-related
emergency line was not included as it was assumed that
service users in the public sector would make use of
general emergency medical services.
Thirdly, cost measurement relied largely on the UPFS
and NHLS pricelists. Whilst there are obvious limitations
in applying such generic guidelines in the estimation of
costs, the scarcity of costing information relating to
diabetes in the South African context made it difficult
to find alternatives. Furthermore, these guidelines are used
in actual practice. The UPFS, for example, provides a
national standard for the billing of patients accessing
provincial health facilities and guides medical schemes
in reimbursing these facilities following the provision of
services to their beneficiaries [41].
Fourthly, the use of LYG as an outcome measure con-
strained the study to mortality/fatality analysis. This was a
limitation given the substantial morbidity arising from the
microvascular complications of diabetes (e.g. renal failure,
diabetic retinopathy) in South Africa [42]. While LYG did
provide for ICER analysis relevant to policy and decision
making, the inclusion of modelling around microvascular
complications could be a valuable complement to this
analysis.
Fifthly, there were limitations resulting from the use of
the UKPDS risk engine. In addition to the obvious difficulty
of applying a United Kingdom-based model to the South
African setting, it is also probable that the treatment of
diabetes, and its co-morbidities, has improved substantially
since the engine was developed (the intervention trial on
which the engine is based was completed in 1997 and the
post-trial programme ended in 2007) [43]. However, while
the risk engine has, indeed, been found to overestimate
true risk, this has been seen as more of a limitation with
regards to individual prognostication [44]. Moreover, the
engine has been deemed to be a suitable tool for resource
prioritization and allocation analysis [44,45].
Conclusions
The growing burden of diabetes represents a major public
health challenge. Along with its resultant morbidity and
mortality, the disease imposes a massive economic cost.
Indeed, a recent report found that the global economic
cost of diabetes is expected to rise from USD 500 billion
in 2010 to approximately USD 745 billion by 2030, with
low- and middle-income countries having to carry a
substantial amount of the burden [46]. Given the resource
constraints existent in South Africa, the identification of
potential ‘best buy’ models of diabetes care is an imperative.
Preliminary analysis using probabilistic modelling found
the capitation intervention model of type 2 diabetes care
to be cost-effective. However, given the difficulty inadapting the DMP to the PHC level in the South African
public sector context, further prospective research is
needed.
A public service-based pilot study could, for example,
allow for the collection of primary data and, consequently,
more robust economic analysis. A pilot study could also
yield information relevant to health services planning, in-
cluding human resource, financial and logistical require-
ments. This could, in turn, inform to the final design of an
implementable, adapted service model. Referral pathways
from such a service to specialist levels of care, where appro-
priate, could also be delineated. Furthermore, prospective
studies could include additional qualitative components
that examine how other factors, such as staff motivation
and multi-disciplinary team dynamics, influence patient
care and health outcomes. Such research could contribute
to an improved, cost-effective model of care for people with
type 2 diabetes within the NHI dispensation.
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